Rapport Therapeutics (RAPP) Interest & Investment Income (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Interest & Investment Income for 4 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income rose 43.12% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $14.9 million (up 11.68% YoY), while the FY2025 annual figure was $13.6 million, up 12.18% from the prior year.
• Interest & Investment Income retreated to $4.4 million in Q1 2026 per RAPP's latest filing, from $4.7 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.7 million in Q4 2025 and bottomed at $221000.0 in Q2 2023.
• Historically, Interest & Investment Income has averaged $2.7 million across 4 years, with a median of $2.9 million in 2025.
• Annual changes were most pronounced in 2024 — Interest & Investment Income soared 1112.22% — and 2025, when it declined 25.4%.
• Rapport Therapeutics' Interest & Investment Income stood at $1.4 million in 2023, then surged by 157.53% to $3.5 million in 2024, then surged by 34.03% to $4.7 million in 2025, then fell by 8.18% to $4.4 million in 2026.
• Business Quant data shows RAPP's Interest & Investment Income at $4.4 million in Q1 2026, $4.7 million in Q4 2025, and $3.1 million in Q3 2025.